Description

KENADION 1 MG INJ 0.5ML

Indications

KENADION 1 MG INJ 0.5ML, containing the active ingredient phytonadione (Vitamin K1), is primarily indicated for the prevention and treatment of Vitamin K deficiency. This condition can arise in various clinical scenarios, including malabsorption syndromes, prolonged antibiotic therapy, and in patients with liver disease. Additionally, KENADION is used to counteract the effects of anticoagulant medications, particularly in cases of overdose or excessive anticoagulation. It is also indicated for newborns to prevent hemorrhagic disease, a condition caused by Vitamin K deficiency.

Mechanism of Action

Phytonadione, the active component of KENADION, plays a crucial role in the synthesis of certain clotting factors in the liver, including factors II (prothrombin), VII, IX, and X. These factors are essential for normal blood coagulation. Vitamin K acts as a cofactor for the enzyme gamma-glutamyl carboxylase, which modifies these clotting factors, allowing them to bind calcium ions and thus become biologically active. By replenishing Vitamin K levels in the body, KENADION effectively restores the synthesis of these clotting factors, thereby promoting hemostasis.

Pharmacological Properties

KENADION is administered via intramuscular injection, allowing for rapid absorption and onset of action. The pharmacokinetics of phytonadione indicate that it is well absorbed from the gastrointestinal tract and has a half-life of approximately 1.5 to 3 hours. However, the duration of action may vary depending on the dose and the individual’s metabolic rate. Phytonadione is predominantly metabolized in the liver, and its metabolites are excreted in the urine. The pharmacological properties of KENADION make it an effective therapeutic agent in managing Vitamin K deficiency and its related complications.

Contraindications

KENADION should not be administered to individuals who have a known hypersensitivity to phytonadione or any of the excipients in the formulation. Additionally, caution is advised in patients with a history of thrombosis or those who are currently undergoing anticoagulant therapy, as inappropriate use may lead to thromboembolic events. It is also contraindicated in cases of severe liver disease, where the synthesis of clotting factors may be impaired despite the administration of Vitamin K.

Side Effects

While KENADION is generally well tolerated, some patients may experience side effects. Commonly reported adverse reactions include pain or irritation at the injection site, allergic reactions, and rare instances of anaphylaxis. Other potential side effects may include dizziness, headache, and gastrointestinal disturbances such as nausea or vomiting. It is important for healthcare providers to monitor patients for any adverse reactions, particularly following the initial administration of the injection.

Dosage and Administration

The dosage of KENADION 1 MG INJ 0.5ML varies depending on the indication and the patient’s condition. For the treatment of Vitamin K deficiency in adults, the typical dose is 1 to 10 mg administered intramuscularly, with repeat doses as necessary based on the clinical response and laboratory monitoring of coagulation parameters. In newborns, a single dose of 0.5 to 1 mg is recommended to prevent hemorrhagic disease, administered intramuscularly shortly after birth. It is essential to follow the prescribing physician’s recommendations and adjust the dosage according to individual patient needs and response to therapy.

Interactions

KENADION may interact with several medications, particularly anticoagulants such as warfarin. The effectiveness of warfarin can be diminished by the administration of Vitamin K, leading to a potential risk of thromboembolic events. Therefore, it is crucial for healthcare providers to monitor the International Normalized Ratio (INR) in patients receiving both KENADION and anticoagulant therapy. Other interactions may occur with certain antibiotics, such as cephalosporins, which can disrupt Vitamin K synthesis and exacerbate deficiency. Patients should inform their healthcare providers of all medications they are taking to avoid potential interactions.

Precautions

Before administering KENADION, healthcare providers should conduct a thorough assessment of the patient’s medical history and current medications. Special precautions should be taken in patients with liver disease, as their ability to synthesize clotting factors may be compromised. Additionally, caution is warranted in pregnant and breastfeeding women, as the safety of phytonadione in these populations has not been fully established. Monitoring coagulation parameters is essential during treatment to ensure therapeutic effectiveness and safety.

Clinical Studies

Clinical studies have demonstrated the efficacy of KENADION in treating and preventing Vitamin K deficiency. Research indicates that administration of phytonadione significantly improves coagulation parameters in patients with malabsorption syndromes and those receiving long-term antibiotic therapy. In neonates, prophylactic administration of KENADION has been shown to reduce the incidence of hemorrhagic disease, highlighting its importance in pediatric care. Ongoing studies continue to explore the optimal dosing regimens and potential applications of KENADION in various clinical settings.

Conclusion

KENADION 1 MG INJ 0.5ML is a vital therapeutic agent in the management of Vitamin K deficiency and its associated complications. Its mechanism of action, pharmacological properties, and clinical efficacy make it an essential tool in both adult and pediatric medicine. Healthcare providers must be aware of the potential contraindications, side effects, and interactions associated with this medication to ensure safe and effective treatment. Continued research and clinical studies will further elucidate the role of KENADION in various clinical scenarios, ultimately enhancing patient care.